Lenvatinib in combination with pembrolizumab is being developed as a first-line therapy for adults
with programmed death-ligand 1 (PD-L1) expressing recurrent or metastatic head and neck
squamous cell carcinoma (HNSCC). HNSCC is a cancer of the mouth, nose or throat that develops
in the squamous cells found in the outer layer of skin and the mucous membranes that line body
cavities. About a half of the patients with HNSCC have it return after treatment (recurrent) or it
spread to other parts of the body (metastatic). Recurrent/metastatic HNSCC is a difficult disease
to treat, with poor prognosis and survival rates.
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Lenvatinib in combination with pembrolizumab is being developed as a first-line therapy for adults with programmed death-ligand 1 (PD-L1) expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). HNSCC is a cancer of the mouth, nose or throat that develops in the squamous cells found in the outer layer of skin and the mucous membranes that line body cavities
Therapeutic Areas:
Head and Neck Cancer
Year:
2022